Evidence map›Paper›PMID 40973891›Full record

ArticleDrug delivery and translational research2026

Bioavailability enhancement and neuropharmacological effects of Dauricine under intranasal administration to improve cognitive impairment via PI3K/AKT/mTOR pathway.

Ruiye Xie, Zhen Liu, Jingjing Zheng, Qiwen Tan, Haitao Wu, Yong Liang

Abstract read
PubMed Publisher
In one paragraph

Article in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ruiye Xie *Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China.
Zhen Liu *Department of Chemistry & the MOE Key Laboratory of Spectrochemical Analysis and Instrumentation, College of Chemistry and Chemical Engineering, Xiamen University, Xiamen, 361005, China.
Jingjing Zheng *Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China.
Qiwen TanScience and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China.
Haitao WuScience and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China.
Yong LiangScience and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China. liangyong@gzucm.edu.cn.ORCID 0000-0002-3749-9541

Funding

Basic and Applied Basic Research Foundation of Guangdong Province 2025A1515010474
6 · The paper itself

Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder strongly associated with aging, and Dauricine (DAU) has demonstrated significant neuropharmacological properties for AD treatment. However, its bioavailability is significantly limited when administered orally, leaving the mechanisms underlying its effects on AD largely unexplored. In this study, a DAU-loaded thermosensitive gel was formulated for delivery via the nasal-nerve route, and its potential to enhance the bioavailability of DAU in rat plasma and cerebrospinal fluid (CSF) was assessed through a pharmacokinetic study. The anti-Alzheimer's disease (AD) mechanism of DAU was investigated using network pharmacology approaches, molecular docking, and dynamics simulations, complemented by in vivo experimental validation. DAU can be effectively incorporated into a thermosensitive gel and administered to the brain within 30 min via intranasal delivery. Following nasal administration, the pharmacokinetic parameters of DAU in cerebrospinal fluid and plasma were significantly elevated compared to oral administration (

Indexed as

BenzylisoquinolinesCognitive DysfunctionAdministration, IntranasalAlzheimer DiseaseAnimalsBiological AvailabilityBrainMaleMolecular Docking SimulationPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRatsRats, Sprague-DawleySignal TransductionTetrahydroisoquinolinesTOR Serine-Threonine KinasesBenzylisoquinolinesdauricinemTOR protein, ratPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktTetrahydroisoquinolinesTOR Serine-Threonine KinasesAlzheimer’s disease; dauricineBioavailability enhancementIntranasal administrationPI3K/AKT/mTOR pathway

Identifiers

PMID40973891

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.